GLP-1 for Weight Loss: Semaglutide, Tirzepatide, and What Comes Next

How GLP-1 Receptor Agonists Actually Work

Glucagon-like peptide-1 (GLP-1) is a hormone your gut releases after you eat. It tells your pancreas to produce insulin, slows gastric emptying so food moves through your stomach more slowly, and sends satiety signals to appetite centers in your brain. In people without obesity, this system works smoothly. You eat, GLP-1 rises, and you eventually feel full.

GLP-1 receptor agonists are synthetic versions of this hormone, engineered to last much longer in the body. Natural GLP-1 breaks down within minutes. Semaglutide, by contrast, has a half-life of about a week, which is why it works as a once-weekly injection [1].

But the weight loss effects go beyond just mimicking a gut hormone. These drugs act directly on the hypothalamus and brainstem, reducing what researchers call “food noise,” the near-constant mental preoccupation with eating that many people with obesity describe. Patients frequently report that they simply stop thinking about food between meals, which is a qualitative change that calorie counting and willpower cannot replicate [2].

There is also growing evidence that GLP-1 agonists reduce the rewarding properties of food. Functional MRI studies show decreased activation in brain reward centers when patients on semaglutide view images of highly palatable foods. This same mechanism appears to explain early reports of reduced alcohol and nicotine cravings in some patients, though those applications remain investigational.

Semaglutide: The STEP Trial Data

Semaglutide is marketed as Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). The weight loss doses are higher: Wegovy goes up to 2.4 mg weekly, while Ozempic maxes out at 2.0 mg.

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program provides the strongest evidence base:

• STEP 1: 1,961 adults without diabetes. Semaglutide 2.4 mg produced 14.9% body weight loss versus 2.4% with placebo at 68 weeks [3].
• STEP 2: In patients with type 2 diabetes, weight loss was somewhat lower at 9.6%, consistent with the known difficulty of losing weight when insulin resistance is present.
• STEP 3: Combined with intensive behavioral therapy, semaglutide produced 16% body weight loss.
• STEP 5: A two-year extension showing sustained weight loss of 15.2% at 104 weeks, demonstrating durability as long as treatment continues.

To put this in context: a person weighing 250 pounds could expect to lose roughly 37 pounds on semaglutide. That’s meaningful. It’s in the range where metabolic parameters like blood pressure, lipids, HbA1c, and liver fat begin to improve substantially.

The SELECT trial added cardiovascular outcome data, showing a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in people with obesity and established cardiovascular disease, independent of diabetes status [4]. This was a landmark finding because it established that the cardiovascular benefits were not simply a downstream effect of blood sugar control.

Tirzepatide: The Dual Agonist Advantage

Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for weight management) targets two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism appears to produce greater weight loss than GLP-1 alone.

The SURMOUNT trial program tells the story:

• SURMOUNT-1: 2,539 adults without diabetes. At the highest dose (15 mg), tirzepatide produced 20.9% body weight loss at 72 weeks versus 3.1% with placebo [5]. That’s a 50-pound loss for a 250-pound person.
• SURMOUNT-2: In patients with type 2 diabetes, the highest dose produced 14.7% weight loss.
• SURMOUNT-3: Combined with intensive lifestyle intervention, weight loss reached 26.6% at the top dose.

These numbers approach what bariatric surgery delivers, which has been the benchmark for decades. Roux-en-Y gastric bypass typically produces 25-30% total body weight loss, and sleeve gastrectomy about 20-25%.

Head-to-head data is limited, but the available evidence suggests tirzepatide produces meaningfully more weight loss than semaglutide at their respective maximum doses. Whether this translates to greater cardiovascular benefit is being tested in ongoing trials.

Injectable vs. Oral: Where Things Stand

Most people start on weekly subcutaneous injections using an auto-injector pen. The needle is small and the injection is straightforward, but needle aversion is real and it remains a barrier for some patients.

Oral semaglutide (Rybelsus) is available for diabetes but is being studied at higher doses for weight management. The challenge is bioavailability: oral semaglutide must be taken on an empty stomach with a small sip of water, then nothing to eat or drink for 30 minutes. Even under perfect conditions, only about 1% of the drug is absorbed. Higher-dose oral formulations are in late-stage trials.

Orforglipron, a non-peptide oral GLP-1 agonist from Eli Lilly, may change this. Because it’s a small molecule rather than a peptide, it doesn’t face the same absorption limitations. Phase 2 data showed roughly 14.7% weight loss at 36 weeks, with phase 3 trials underway [6]. If approved, it could dramatically expand access by simplifying the dosing regimen and potentially lowering manufacturing costs.

Side Effects: What to Expect and What to Watch For

The most common side effects are gastrointestinal, and they’re directly related to the mechanism of action. Slowing gastric emptying means food sits in the stomach longer, which can cause:

• Nausea (40-50% of patients, typically worst during dose titration)
• Vomiting (about 25%)
• Diarrhea (about 30%)
• Constipation (about 25%)

These effects are dose-dependent and usually improve over time. The slow dose-escalation schedule (starting at 0.25 mg and increasing every 4 weeks) exists specifically to minimize GI symptoms. Most patients find them manageable after the first 2-3 months.

More serious concerns include:

• Gastroparesis-like symptoms: In a small percentage of patients, gastric emptying slows dramatically, causing severe nausea, vomiting, and abdominal pain that persists even after stopping the medication. Case reports have documented this, though large-scale incidence data is limited.
• Pancreatitis: A theoretical risk based on the mechanism. Clinical trial data has not shown a statistically significant increase, but patients with a history of pancreatitis should avoid these medications [7].
• Gallbladder disease: Rapid weight loss from any cause increases gallstone risk. GLP-1 agonists also directly affect gallbladder motility. The STEP trials showed a 2-3x increase in gallbladder-related events.
• Thyroid concerns: Animal studies showed increased medullary thyroid cancer in rodents at very high doses. This has not been observed in humans, but the drugs carry a boxed warning and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

The Muscle Mass Problem

This is the concern that doesn’t get enough attention. When you lose weight through any method, roughly 25-40% of the weight lost is lean mass (muscle, bone, water) rather than fat. With GLP-1 agonists, the ratio appears similar, and in some studies it may be worse because the appetite suppression is so strong that patients eat inadequately [8].

Losing muscle matters. Muscle is your primary glucose disposal tissue, the main driver of resting metabolic rate, and a critical determinant of functional capacity as you age. Losing 30 pounds is counterproductive if 12 of those pounds are muscle.

Mitigation strategies supported by evidence:

• Protein intake: Target 1.2-1.6 g per kg of body weight daily, with at least 30 g per meal. This is challenging when appetite is suppressed, and protein supplements or high-protein snacks may be necessary.
• Resistance training: 2-3 sessions per week of progressive resistance exercise. This is probably the single most important thing you can do while on a GLP-1 agonist.
• Adequate caloric intake: Some patients on GLP-1 agonists eat as few as 800-1,000 calories daily, which is too low to preserve muscle. Working with a dietitian to maintain a moderate deficit (rather than an extreme one) is worthwhile.
• Creatine supplementation: 3-5 g daily supports muscle protein synthesis and exercise performance during caloric restriction.

Who Is a Good Candidate?

FDA-approved indications for the weight management formulations (Wegovy, Zepbound) include adults with:

• BMI of 30 or higher (obesity), or
• BMI of 27 or higher (overweight) with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea

Beyond the formal criteria, better candidates tend to be people who have tried lifestyle modifications but have strong biological drivers of overeating, such as persistent hunger despite adequate meals, food preoccupation, or a family history of obesity that suggests a genetic predisposition.

Poor candidates include those looking to lose vanity weight (5-10 pounds), people with a history of medullary thyroid carcinoma, those with active pancreatitis or severe gastroparesis, and people who are unwilling to commit to long-term use, given the weight regain data.

Cost and Insurance: The Uncomfortable Reality

At list price, Wegovy and Zepbound cost roughly $1,000-1,300 per month. Insurance coverage is inconsistent. Many employer-sponsored plans have added coverage, but Medicare currently does not cover anti-obesity medications (though legislation to change this is pending), and Medicaid coverage varies by state.

Manufacturer savings programs can reduce costs for commercially insured patients, but the out-of-pocket burden remains significant for many people. This has created enormous demand for compounded versions of semaglutide and tirzepatide, which can cost $150-400 per month.

The compounding pharmacy situation is complicated. During drug shortages, the FDA allowed compounding pharmacies to produce semaglutide and tirzepatide. As shortages resolve, the legal basis for compounding becomes less clear, and the brand manufacturers have pushed back aggressively. Quality control at compounding pharmacies is also more variable than at major pharmaceutical manufacturing facilities. Patients using compounded versions should ensure their pharmacy is accredited by the PCAB or state board of pharmacy.

What Happens When You Stop?

This is the question many patients don’t ask early enough. The STEP 1 extension trial showed that participants who stopped semaglutide after 68 weeks regained roughly two-thirds of their lost weight over the following year [9]. Appetite returned to baseline, food noise came back, and the biological drive to eat reasserted itself.

This isn’t a failure of willpower. Obesity involves long-term changes to appetite-regulating hormones, gut microbiota, and brain reward circuitry. A 68-week drug course doesn’t reset those systems permanently, just as stopping blood pressure medication doesn’t cure hypertension.

The practical implication is that GLP-1 agonists, for most people, are a long-term or indefinite treatment. Some patients can taper to a lower maintenance dose once they reach their goal weight, and there’s interest in intermittent dosing strategies, but the evidence base for these approaches is thin. If you’re considering starting a GLP-1 agonist, go in with the expectation that you may need to stay on it.

What’s Coming Next

The pipeline is crowded and competitive. The most interesting agents:

• Retatrutide (Eli Lilly): A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 data showed up to 24.2% body weight loss at 48 weeks, and phase 3 trials are enrolling [10]. The glucagon receptor component may provide additional benefits for liver fat reduction.
• Survodutide (Boehringer Ingelheim): A GLP-1/glucagon dual agonist showing particular promise for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), with significant reductions in liver fat content.
• Orforglipron (Eli Lilly): The oral non-peptide GLP-1 agonist mentioned earlier, which could eliminate the need for injections entirely.
• Amycretin (Novo Nordisk): A GLP-1/amylin dual agonist. Phase 1 data showed 13% weight loss in just 12 weeks, suggesting potentially faster onset than current options.

The direction is clear: multi-receptor agonists that produce greater weight loss with potentially fewer side effects, in both injectable and oral formulations.

Optimizing Lifestyle While on a GLP-1 Agonist

These drugs work best as part of a broader strategy, not as a standalone solution. Practical recommendations for patients currently on GLP-1 therapy:

• Prioritize protein at every meal. When your appetite is suppressed and you’re only eating 1,200-1,500 calories, every bite needs to count. Lean meats, fish, eggs, Greek yogurt, and protein supplements should be the foundation of your diet.
• Strength train consistently. This is non-negotiable for preserving muscle mass. Even 2 sessions per week of full-body resistance training makes a measurable difference.
• Stay hydrated. Reduced food intake means less water from food. Many patients on GLP-1 agonists become mildly dehydrated without realizing it.
• Monitor for nutrient deficiencies. Lower food intake means lower micronutrient intake. A daily multivitamin and periodic blood work (vitamin D, B12, iron, magnesium) is reasonable.
• Don’t skip meals. Even if you’re not hungry, eating small, protein-rich meals at regular intervals supports muscle preservation and prevents the binge-restrict cycle.

GLP-1 agonists are powerful tools. They work through real biological mechanisms, produce clinically meaningful weight loss, and improve cardiometabolic outcomes. But they are not magic, and they work far better when combined with the foundational behaviors that support metabolic health long-term: resistance training, adequate protein, quality sleep, and stress management.

Related Reading

• Metabolic Health: The Complete Guide (Pillar)
• Metabolic Syndrome: Can It Be Reversed Without Medication?
• Insulin Resistance: Early Signs and What to Do About Them
• GLP-1 Agonists and Inflammation: What the Research Shows
• PCOS Treatment Options: Evidence-Based Approaches

References

1. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol. 2019;10:155. doi:10.3389/fendo.2019.00155
2. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242-1251. doi:10.1111/dom.12932
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
6. Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877-888. doi:10.1056/NEJMoa2302392
7. Storgaard H, Cold F, Gluud LL, Vilsboll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):906-908. doi:10.1111/dom.12885
8. Conte C, Cecere A, Corradi F, et al. Muscle mass and fat mass changes with GLP-1 receptor agonist therapy: a systematic review and meta-analysis. Obesity. 2024;32(1):10-22. doi:10.1002/oby.23927
9. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
10. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972